Cefotaxime and amikacin: results of in vitro and in vivo studies against Gram-negative bacteria and Staphylococcus aureus. EORTC International Antimicrobial Therapy Project Group.
D000583:Amikacin / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy; D002439:Cefotaxime; D002511:Cephalosporins / Q000494:pharmacology* / Q000627:therapeutic use; D004357:Drug Synergism; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D051379:Mice; D013211:Staphylococcus aureus / Q000187:drug effects*
D002511:Cephalosporins; D007612:Kanamycin; D000583:Amikacin; D002439:Cefotaxime